NEW YORK (GenomeWeb) – Merck KGaA and Pfizer announced on Thursday a deal with Dako to develop a companion diagnostic test for the drug firms' investigational immune checkpoint inhibitor avelumab. 

The firms will collaborate on developing the test to evaluate programmed death-ligand 1 protein expression levels in tumor tissue and its microenvironment, including immune cells associated with tumors, Merck and Pfizer said, adding that the investigational CDx is part of the protocols in ongoing trials for avelumab. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.